|
|
Biomarkers for Detection and Prediction of Chemotherapy-Related Cognitive Impairment |
| 3P30CA014520-48S5 |
|
NCI |
2022 |
|
|
Psychosocial Risk in Young Survivors of Early Onset Pediatric Cancer: The Role of Physical and Neurocognitive Late Effects |
| 3R01CA248103-02S1 |
|
NCI |
2022 |
|
|
Psychosocial Risk in Young Survivors of Early Onset Pediatric Cancer: The Role of Physical and Neurocognitive Late Effects |
| 3R01CA248103-02S2 |
|
NCI |
2022 |
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia |
| 5K07CA218362-05 |
|
NCI |
2022 |
|
|
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors |
| 5R01CA172145-08 |
|
NCI |
2022 |
|
|
Predicting Long-Term Chemotherapy-Related Cognitive Impairment |
| 5R01CA226080-04 |
|
NCI |
2022 |
|
|
Psychosocial Risk in Young Survivors of Early Onset Pediatric Cancer: The Role of Physical and Neurocognitive Late Effects |
| 5R01CA248103-02 |
|
NCI |
2022 |
|
|
Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. |
| 5R01CA249988-02 |
|
NCI |
2022 |
|
|
Image-guided combination therapies for radiotherapy-induced neurocognitive impairment in pediatric brain tumor survivors |
| 5R01CA262887-02 |
|
NCI |
2022 |
|
|
Candidate mechanisms for chemotherapy-induced neurocognitive deficits in pediatric solid non-CNS tumor patients |
| 5R21CA262491-02 |
|
NCI |
2022 |
